Detalhe da pesquisa
1.
Outcomes at 3 years posttransplant in imlifidase-desensitized kidney transplant patients.
Am J Transplant
; 21(12): 3907-3918, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34236770
2.
The Bacterial Enzyme IdeS Cleaves the IgG-Type of B Cell Receptor (BCR), Abolishes BCR-Mediated Cell Signaling, and Inhibits Memory B Cell Activation.
J Immunol
; 195(12): 5592-601, 2015 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26553074
3.
Imlifidase-generated Single-cleaved IgG: Implications for Transplantation.
Transplantation
; 106(7): 1485-1496, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34966107
4.
IgM single antigen bead HLA-assay is affected by imlifidase through the cleavage of IgG but not IgM.
Transpl Immunol
; 68: 101436, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34265468
5.
Imlifidase Desensitization in Crossmatch-positive, Highly Sensitized Kidney Transplant Recipients: Results of an International Phase 2 Trial (Highdes).
Transplantation
; 105(8): 1808-1817, 2021 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33093408
6.
Enzymatic Inactivation of Endogenous IgG by IdeS Enhances Therapeutic Antibody Efficacy.
Mol Cancer Ther
; 16(9): 1887-1897, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28533435
7.
Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-beta k.o. and wild type mice.
J Neuroimmunol
; 173(1-2): 69-78, 2006 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-16472873
8.
Complete Removal of Extracellular IgG Antibodies in a Randomized Dose-Escalation Phase I Study with the Bacterial Enzyme IdeS--A Novel Therapeutic Opportunity.
PLoS One
; 10(7): e0132011, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26177518
9.
Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship.
J Med Chem
; 47(8): 2075-88, 2004 Apr 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-15056005
10.
The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis.
J Neuroimmunol
; 130(1-2): 163-72, 2002 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-12225898